CD44 and gastric cancer: In GC, CD44 was the first CSC biomarker proposed when Takaishi and collaborators found that the fraction of CD44+ cells isolated from GC cell lines exhibited self-renewal capacity in vitro and tumorigenic potential in immunodeficient mice, being these properties abrogated by CD44 silencing.